Citations

Clear

4 citation(s) found for "Javaid, Mahnoor".

Differential cardiotoxicity of acalabrutinib versus chemoimmunotherapy in chronic lymphocytic leukemia: A retrospective cohort study from 2000-2025 using TriNetX database.
Qadeer, Abdul , Aslam, Raza, Kansal, Prishavi, Seena, P, Sajid, Ahmed , Ahmed, Manahil , Rath, Shree , Khan, Aoun Zaib , Javaid, Mahnoor , Jumean, Samer, Khan, Allahdad , Kansal, Prishavi, Rath, Shree , Javaid, Mahnoor, Jumean, Samer, Kirchoff, Robert W.

Mayo Clinic

Journal of Clinical Oncology | May 28, 2025 | Volume: 43 | Issue: 16_suppl | Pages: No page available

10.1200/jco.2025.43.16_suppl.e19022 Get It

e19022 Background: Chronic lymphocytic leukemia (CLL) is a common adult leukemia that originates by dysfunctional development of the lymphocytes. Acalabrutinib, a second-generation Bruton’s tyrosine kinase (BTK) inhibitor, has demonstrated promising outcomes as a targeted therapy alternative to chemoimmunotherapy for treating CLL. The objective of this retrospective analysis was to compare the safety profiles of acalabrutinib and chemoimmunotherapy in patients with CLL and to evaluate the potential of acalabrutinib as an alternative therapeutic option. Methods: We conducted a retrospective cohort analysis using the TriNetX platform analyzing data of patients diagnosed with CLL from January, 2000 to January, 2025. Data was classified into cohorts on the basis of treatment with either acalabrutinib or chemoimmunotherapy. Propensity score matching analysis was carried out to balance their demographic and clinical characteristics. Demographic factors included age (≥18 years), sex, race, and ethnicity. Outcomes assessed included all cause death, atrial fibrillation, hypertension, acute heart failure, ventricular arrythmias, and bleeding. Kaplan-Meier survival analysis was employed. Results: A total of 4,006 patients were included in the analysis, 847 received acalabrutinib and 3,172 underwent chemoimmunotherapy, with a mean age of 70±11 and 69±14 years respectively. Participants were mostly male, with the majority of the patients being non-Hispanic Whites. Median period of follow up was 578 and 925 days respectively, incidence and risk of mortality and adverse events were assessed. A lower risk of mortality was noted with acalabrutinib (RR: 0.407; 95%CI: 0.32, 0.51; p<0.0001). Additionally, atrial fibrillation developed in fewer than 10 patients on use of acalabrutinib, thus carrying significantly lower odds (odds ratio (OR):0.3; 95%CI: 0.16, 0.58; p=0.001) than chemoimmunotherapy, which reported atrial fibrillation in 120 patients. Similarly, significantly lesser incidence of hypertension was noted on use of acalabrutinib, implying safer drug profile. Bleeding risk was also reduced in the acalabrutinib cohort and was statistically significant (OR:0.36, 95%CI: 0.24, 0.52; p<0.0001). The odds of acute heart failure (OR:1.25, 95%CI: 0.61, 2.57; p=0.54) and ventricular arrhythmia (OR:1.5, 95%CI: 0.72, 3.14; p=0.2) were statistically nonsignificant. Conclusions: The use of acalabrutinib in patients with CLL was associated with statistically significant better safety profile, with lesser risk of mortality, bleeding events and atrial fibrillation. Clinicians may consider using acalabrutinib as a superior treatment modality in the treatment of CLL. Further research maybe required to optimize treatment protocols in the best interest of patients.
The impact of multimorbidity on Quality of Life in inflammatory myopathies: A cluster analysis from the COVAD dataset
Fornaro, Marco , Venerito, Vincenzo , Pellico, Maria Rosa , Iannone, Florenzo , Joshi, Mrudula , Chen, Yi‐Ming , Tan, Ai Lyn , Saha, Sreoshy , Chatterjee, Tulika , Agarwal, Vishwesh , Kadam, Esha , Hasan, A T M Tanveer , Shumnalieva, Russka , Milchert, Marcin , Tan, Chou Luan , Vaidya, Binit , Kuwana, Masataka , Shaharir, Syahrul Sazliyana , Tehozol, Erick Adrian Zamora , Gutiérrez, Carlos Enrique Toro , Goo, Phonpen Akawatcharangura , Katchamart, Wanruchada , Parodis, Ioannis , Nikiphorou, Elena , Chinoy, Hector , Agarwal, Vikas , Gupta, Latika, Group, CoVAD Study, Sen, Parikshit, Javaid, Mahnoor, Andreoli, Laura, Lini, Daniele, Schreiber, Karen, Nune, Arvind, Tan, Ai Lyn, Patel, Aarat, Pauling, John D, Wincup, Chris, Barman, Bhupen, Torre, Ignacio García-De La, Colunga-Pedraza, Iris J, Merayo-Chalico, Javier, Chibuzo, Okwara Celestine, Kibbi, Lina El, Lilleker, James B, Salim, Babur, Gheita, Tamer, Saavedra, Miguel A, Griger, Zoltán, Kardes, Sinan, Vince, Melinda Nagy, Singh, Yogesh Preet, Ranjan, Rajiv, Jain, Avinash, Pandya, Sapan C, Pilania, Rakesh Kumar, Sharma, Aman, M, Manesh Manoj, Gupta, Vikas, Kavadichanda, Chengappa G, Patro, Pradeepta Sekhar, Ajmani, Sajal, Phatak, Sanat, Goswami, Rudra Prosad, Chowdhury, Abhra Chandra, Mathew, Ashish Jacob, Shenoy, Padnamabha, Asranna, Ajay, Bommakanti, Keerthi Talari, Shukla, Anuj, Pande, Arunkumar R, Chandwar, Kunal, Ghodke, Akanksha, Boro, Hiya, Fazal, Zoha Zahid, Vaidya, Binit, Cansu, Döndü Üsküdar, Yıldırım, Reşit, Gasparyan, Armen Yuri, Papa, Nicoletta Del, Sambataro, Gianluca, Fabiola, Atzeni, Govoni, Marcello, Parisi, Simone, Bocci, Elena Bartoloni, Sebastiani, Gian Domenico, Fusaro, Enrico, Sebastiani, Marco, Quartuccio, Luca, Franceschini, Franco, Sainaghi, Pier Paolo, Orsolini, Giovanni, Angelis, Rossella De, Danieli, Maria Giovanna, Grignaschi, Silvia, Giollo, Alessandro, Alunno, Alessia, Traboco, Lisa S, Wibowo, Suryo Anggoro Kusumo, Loarce-Martos, Jesús, Prieto-González, Sergio, Gonzalez, Raquel Aranega, Yoshida, Akira, Nakashima, Ran, Sato, Shinji, Kimura, Naoki, Kaneko, Yuko, Gono, Takahisa, Tomaras, Stylianos, Proft, Fabian Nikolai, Holzer, Marie-Therese, Gromova, Margarita Aleksandrovna, Aharonov, Or, Griger, Zoltán, Hmamouchi, Ihsane, bouchti, Imane El, Baba, Zineb, Giannini, Margherita, Maurier, François, Campagne, Julien, Meyer, Alain, Langguth, Daman, Limaye, Vidya, Needham, Merrilee, Srivastav, Nilesh, Hudson, Marie, Landon-Cardinal, Océane, Zuleta, Wilmer Gerardo Rojas, Arbeláez, Álvaro, Cajas, Javier, Silva, José António Pereira, Fonseca, João Eurico, Zimba, Olena, Ima-Edomwonyi, Uyi, Dedeke, Ibukunoluwa, Airenakho, Emorinken, Madu, Nwankwo Henry, Yerima, Abubakar, Olaosebikan, Hakeem, Becky, A, Koussougbo, Oruma Devi, Palalane, Elisa, So, Ho, Ugarte-Gil, Manuel Francisco, Chinchay, Lyn, Bernaola, José Proaño, Pimentel, Victorio, Fathi, Hanan Mohammed, Mohammed, Reem Hamdy A, Harifi, Ghita, Fuentes-Silva, Yurilís, Cabriza, Karoll, Losanto, Jonathan, Colaman, Nelly, Cachafeiro-Vilar, Antonio, Bautista, Generoso Guerra, Ho, Enrique Julio Giraldo, González, Raúl, Nunez, Lilith Stange, M, Cristian Vergara, Báez, Jossiell Then, Alonzo, Hugo, Pastelin, Carlos Benito Santiago, Salinas, Rodrigo García, Obiols, Alejandro Quiñónez, Chávez, Nilmo, Ordóñez, Andrea Bran, Argueta, Sandra, Llerena, Gil Alberto Reyes, Sierra-Zorita, Radames, Arrieta, Dina, Hidalgo, Eduardo Romero, Saenz, Ricardo, M, Idania Escalante, Morales, Roberto, Calapaqui, Wendy, Quezada, Ivonne, Arredondo, Gabriela, Pauling, John D , Wincup, Chris , Sambataro, Gianluca , Angelis, Rossella De , Loarce‐Martos, Jesus , Lini, Daniele , Fuentes-Silva, Yurilís , Giollo, Alessandro , Grignaschi, Silvia , Schreiber, Karen , Danieli, Maria Giovanna , Gupta, Latika , Shinjo, Samuel Katsuyuki , Hoff, Leonardo Santos , Kadam, Esha , Ziade, Nelly , Velikova, Tsvetelina , Hasan, A T M Tanveer , Shumnalieva, Russka , Milchert, Marcin , Tan, Chou Luan , Gracia-Ramos, Abraham Edgar , Cavagna, Lorenzo , Vaidya, Binit , Kuwana, Masataka , Sazliyana Shaharir, Syahrul , Knitza, Johannes , Makol, Ashima , Zamora Tehozol, Erick Adrian , Rojas Serrano, Jorge , Halabi, Hussein , Dey, Dzifa , Gutiérrez, Carlos Enrique Toro , Distler, Oliver , Katchamart, Wanruchada , Day, Jessica , Parodis, Ioannis , Nikiphorou, Elena , Chinoy, Hector , Agarwal, Vikas , Gupta, Latika , Joshi, Mrudula , Agarwal, Vishwesh , Tan, Ai Lyn , Chatterjee, Tulika , Pauling, John D , Wincup, Chris , Chen, Yi-Ming , Saha, Sreoshy , De Angelis, Rossella , Iannone, Florenzo , Shinjo, Samuel Katsuyuki , Ziadé, Nelly , Velikova, Tsvetelina , Gracia‐Ramos, Abraham Edgar , Makol, Ashima , Halabi, Hussein , Dey, Dzifa , Caballero‐Uribe, Carlo V. , Distler, Oliver , Day, Jessica , Group, CoVAD Study, Sen, Parikshit, Javaid, Mahnoor, Andreoli, Laura, Nune, Arvind, Tan, Ai Lyn, Patel, Aarat, Barman, Bhupen, Torre, Ignacio García-De La, Colunga-Pedraza, Iris J, Merayo-Chalico, Javier, Chibuzo, Okwara Celestine, Kibbi, Lina El, Lilleker, James B, Salim, Babur, Gheita, Tamer, Saavedra, Miguel A, Griger, Zoltán, Kardes, Sinan, Vince, Melinda Nagy, Singh, Yogesh Preet, Ranjan, Rajiv, Jain, Avinash, Pandya, Sapan C, Pilania, Rakesh Kumar, Sharma, Aman, M, Manesh Manoj, Gupta, Vikas, Kavadichanda, Chengappa G, Patro, Pradeepta Sekhar, Ajmani, Sajal, Phatak, Sanat, Goswami, Rudra Prosad, Chowdhury, Abhra Chandra, Mathew, Ashish Jacob, Shenoy, Padnamabha, Asranna, Ajay, Bommakanti, Keerthi Talari, Shukla, Anuj, Pande, Arunkumar R, Chandwar, Kunal, Ghodke, Akanksha, Boro, Hiya, Fazal, Zoha Zahid, Vaidya, Binit, Cansu, Döndü Üsküdar, Yıldırım, Reşit, Gasparyan, Armen Yuri, Papa, Nicoletta Del, Fabiola, Atzeni, Govoni, Marcello, Parisi, Simone, Bocci, Elena Bartoloni, Sebastiani, Gian Domenico, Fusaro, Enrico, Sebastiani, Marco, Quartuccio, Luca, Franceschini, Franco, Sainaghi, Pier Paolo, Orsolini, Giovanni, Alunno, Alessia, Traboco, Lisa S, Wibowo, Suryo Anggoro Kusumo, Prieto-González, Sergio, Gonzalez, Raquel Aranega, Yoshida, Akira, Nakashima, Ran, Sato, Shinji, Kimura, Naoki, Kaneko, Yuko, Gono, Takahisa, Tomaras, Stylianos, Proft, Fabian Nikolai, Holzer, Marie-Therese, Gromova, Margarita Aleksandrovna, Aharonov, Or, Griger, Zoltán, Hmamouchi, Ihsane, bouchti, Imane El, Baba, Zineb, Giannini, Margherita, Maurier, F. , Campagne, Julien, Meyer, Alain , Langguth, Daman, Limaye, Vidya, Needham, Merrilee, Srivastav, Nilesh, Hudson, Marie, Landon‐Cardinal, Océane , Zuleta, Wilmer Gerardo Rojas, Arbeláez, Álvaro, Cajas, Javier, Silva, José António Pereira, Fonseca, João Eurico, Zimba, Olena, Ima-Edomwonyi, Uyi, Dedeke, Ibukunoluwa, Airenakho, Emorinken, Madu, Nwankwo Henry, Yerima, Abubakar, Olaosebikan, Hakeem, Becky, A, Koussougbo, Oruma Devi, Palalane, Elisa, So, Ho, Ugarte-Gil, Manuel Francisco, Chinchay, Lyn, Bernaola, José Proaño, Pimentel, Victorio, Fathi, Hanan Mohammed, Mohammed, Reem Hamdy A, Harifi, Ghita, Cabriza, Karoll, Losanto, Jonathan, Colaman, Nelly, Cachafeiro-Vilar, Antonio, Bautista, Generoso Guerra, Ho, Enrique Julio Giraldo, González, Raúl, Nunez, Lilith Stange, M, Cristian Vergara, Báez, Jossiell Then, Alonzo, Hugo, Pastelin, Carlos Benito Santiago, Salinas, Rodrigo García, Obiols, Alejandro Quiñónez, Chávez, Nilmo, Ordóñez, Andrea Bran, Argueta, Sandra, Llerena, Gil Alberto Reyes, Sierra-Zorita, Radames, Arrieta, Dina, Hidalgo, Eduardo Romero, Saenz, Ricardo, M, Idania Escalante, Morales, Roberto, Calapaqui, Wendy, Quezada, Ivonne, Arredondo, Gabriela

Mayo Clinic

Rheumatology | September 26, 2024 | Volume: 64 | Issue: 4 | Pages: 2133-2142

10.1093/rheumatology/keae520 | PMID 39324556 Get It

Abstract Objective The presence of comorbidities can substantially affect patients’ quality of life, but data regarding their impact on idiopathic inflammatory myopathies (IIMs) are limited. Methods We examined the prevalence of comorbidities in IIM patients, other autoimmune rheumatic diseases (oAIRDs) and healthy controls (HCs), using data from the self-reported COVAD-2 survey. We defined basic multimorbidity (BM) as the presence of ≥2 non-rheumatic chronic conditions and complex multimorbidity (CM) as the presence of ≥3 non-rheumatic chronic conditions affecting ≥3 organ systems. Hierarchical clustering on principal components was performed for grouping. Results Among the COVAD respondents, 1558 IIMs, 4591 oAIRDs and 3652 HCs were analysed. IIMs exhibited a high burden of comorbidities (odds ratio [OR]: 1.62 vs oAIRDs and 2.95 vs HCs, P &lt; 0.01), BM (OR: 1.66 vs oAIRDs and 3.52 vs HCs, P &lt; 0.01), CM (OR: 1.69 vs AIRDs and 6.23 vs HCs, P &lt; 0.01) and mental health disorders (MHDs) (OR: 1.33 vs oAIRDs and 2.63 vs HCs, P &lt; 0.01). Among the IIM patients, those with comorbidities or MHDs had lower PROMIS Global Physical (PGP), PROMIS Global Mental (PGM), and PROMIS Physical Function (SF10) scores, and higher fatigue (F4a) scores (all P &lt; 0.001). PGP, PGM, SF10a and F4a were influenced by age, active disease, BM and MHDs. Four distinct clusters were identified among the IIMs according to comorbidities and PROMIS scores. Conclusion Patients with IIMs have a higher burden of comorbidities that influence physical and mental health, identifiable as clinical clusters for optimized and holistic management approaches.
Characteristics of emerging new autoimmune diseases after COVID‐19 vaccination: A sub‐study by the COVAD group
Shumnalieva, Russka , Ravichandran, Naveen , Javaid, Mahnoor , Darooka, Naitica , Gonzalez, Daniel E., Velikova, Tsvetelina , Milchert, Marcin , Kuwana, Masataka , Boyd, Peter , Yaadav, Praggya , Cheng, Karen Kow Yip , Kobert, Linda , Gutiérrez, Carlos Enrique Toro , Caballero‐Uribe, Carlo V. , Parodis, Ioannis , Dey, Dzifa , Nikiphorou, Elena , Kadam, Esha , Tan, Ai Lyn , Chinoy, Hector , Gupta, Latika, Group, COVAD Study, Agarwal, Vikas , Tehozol, Erick Adrian Zamora , Gupta, Latika , Javaid, Mahnoor , Darooka, Naitica , Velikova, Tsvetelina , Milchert, Marcin , Kuwana, Masataka , Joshi, Mrudula , Gracia-Ramos, Abraham Edgar , Boyd, Peter , Yaadav, Praggya , Cheng, Karen , Cavagna, Lorenzo , Sen, Parikshit , Day, Jessica , Makol, Ashima , Gutiérrez, Carlos Enrique Toro , Caballero-Uribe, Carlo Vinicio , Saha, Sreoshy , Parodis, Ioannis , Dey, Dzifa , Nikiphorou, Elena , Distler, Oliver , Kadam, Esha , Tan, Ai Lyn , Shinjo, Samuel Katsuyuki , Ziade, Nelly , Knitza, Johannes , Chinoy, Hector , Aggarwal, Rohit , Agarwal, Vikas , Gupta, Latika , Agarwal, Vikas , Naveen, R , Zamora Tehozol, Erick Adrian , Shumnalieva, Russka , Hannah, Jennifer R. , Roy, Debaditya , Joshi, Mrudula , Gracia‐Ramos, Abraham Edgar , Sen, Parikshit , Day, Jessica , Makol, Ashima , Saha, Sreoshy , Distler, Oliver , Shinjo, Samuel Katsuyuki , Ziadé, Nelly , Aggarwal, Rohit , Group, COVAD Study

Mayo Clinic

International Journal of Rheumatic Diseases | May 14, 2024 | Volume: 27 | Issue: 5 | Pages: No page available

10.1111/1756-185x.15178 | PMID 38742751 Get It

AbstractBackgroundDespite the overall safety and efficacy of COVID‐19 vaccinations, rare cases of systemic autoimmune diseases (SAIDs) have been reported post‐vaccination. This study used a global survey to analyze SAIDs in susceptible individuals' post‐vaccination.MethodsA cross‐sectional study was conducted among participants with self‐reported new‐onset SAIDs using the COVID‐19 Vaccination in Autoimmune Diseases (COVAD) 2 study dataset—a validated, patient‐reported e‐survey—to analyze the long‐term safety of COVID‐19 vaccines. Baseline characteristics of patients with new‐onset SAIDs and vaccinated healthy controls (HCs) were compared after propensity score matching based on age and sex in a 1:4 ratio.ResultsOf 16 750 individuals, 74 (median age 52 years, 79.9% females, and 76.7% Caucasians) had new‐onset SAID post‐vaccination, mainly idiopathic inflammatory myopathies (IIMs) (n = 23, 31.51%), arthritis (n = 15; 20.53%), and polymyalgia rheumatica (PMR) (n = 12, 16.40%). Higher odds of new‐onset SAIDs were noted among Caucasians (OR = 5.3; 95% CI = 2.9–9.7; p < .001) and Moderna vaccine recipients (OR = 2.7; 95% CI = 1.3–5.3; p = .004). New‐onset SAIDs were associated with AID multimorbidity (OR = 1.4; 95% CI = 1.1–1.7; p < .001), mental health disorders (OR = 1.6; 95% CI = 1.3–1.9; p < .001), and mixed race (OR = 2.2; 95% CI = 1.2–4.2; p = .010), where those aged >60 years (OR = 0.6; 95% CI = 0.4–0.8; p = .007) and from high/medium human development index (HDI) countries (compared to very high HDI) reported fewer events than HCs.ConclusionThis study reports a low occurrence of new‐onset SAIDs following COVID‐19 vaccination, primarily IIMs, PMR, and inflammatory arthritis. Identified risk factors included pre‐existing AID multimorbidity, mental health diseases, and mixed race. Revaccination was well tolerated by most patients; therefore, we recommend continuing COVID‐19 vaccination in the general population. However, long‐term studies are needed to understand the autoimmune phenomena arising post‐vaccination.
Listening to patients, for the patients: The COVAD Study—Vision, organizational structure, and challenges
Joshi, Mrudula , Darooka, Naitica , Saha, Sreoshy , Dyball, Sarah , Sen, Parikshit , Yaadav, Praggya , Javaid, Mahnoor , Kadam, Esha , Shinjo, Samuel Katsuyuki , Dey, Dzifa , Gutiérrez, Carlos Enrique Toro , Caballero‐Uribe, Carlo V. , Kuwana, Masataka , Burmester, Gerd R , Ziadé, Nelly , Wincup, Chris , Parodis, Ioannis , Tan, Ai Lyn , Wang, Guochun , Dalbeth, Nicola , Velikova, Tsvetelina , Nikiphorou, Elena , Agarwal, Vikas , Gupta, Latika, group, the COVAD study, Tehozol, Erick Adrian Zamora , Alpizar-Rodriguez, D. , Singla, Shikha , Cheng, Karen Kow Yip , Gupta, Latika , Cavagna, Lorenzo , Makol, Ashima , Gutiérrez, Carlos Enrique Toro , Caballero-Uribe, Carlo Vinicio , Kuwana, Masataka , Burmester, Gerd-Rüdiger , Ziade, Nelly , Wincup, Chris , Andreoli, Laura , Parodis, Ioannis , Tan, Ai Lyn , Guillemin, Francis , Knitza, Johannes , Wang, Guochun , Dalbeth, Nicola , Velikova, Tsvetelina , Gracia-Ramos, Abraham Edgar , Nikiphorou, Elena , Day, Jessica , Chinoy, Hector , Aggarwal, Rohit , Agarwal, Vikas , Gupta, Latika , Joshi, Mrudula , Shinjo, Samuel Katsuyuki , Alpízar-Rodríguez, Deshiré , Zamora Tehozol, Erick Adrian , Dey, Dzifa , Sen, Parikshit , Saha, Sreoshy , Darooka, Naitica , Yaadav, Praggya , Cheng, Karen , Kadam, Esha , Makol, Ashima , Andréoli, Laura , Gracia‐Ramos, Abraham Edgar , Day, Jessica , Chinoy, Hector , Aggarwal, Rohit , group, the COVAD study

Mayo Clinic

International Journal of Rheumatic Diseases | May 9, 2024 | Volume: 27 | Issue: 5 | Pages: No page available

10.1111/1756-185x.15161 | PMID 38720408 Get It

AbstractBackgroundThe pandemic presented unique challenges for individuals with autoimmune and rheumatic diseases (AIRDs) due to their underlying condition, the effects of immunosuppressive treatments, and increased vaccine hesitancy.ObjectivesThe COVID‐19 vaccination in autoimmune diseases (COVAD) study, a series of ongoing, patient self‐reported surveys were conceived with the vision of being a unique tool to gather patient perspectives on AIRDs. It involved a multinational, multicenter collaborative effort amidst a global lockdown.MethodsLeveraging social media as a research tool, COVAD collected data using validated patient‐reported outcomes (PROs). The study, comprising a core team, steering committee, and global collaborators, facilitated data collection and analysis. A pilot‐tested, validated survey, featuring questions regarding COVID‐19 infection, vaccination and outcomes, patient demographics, and PROs was circulated to patients with AIRDs and healthy controls (HCs).DiscussionWe present the challenges encountered during this international collaborative project, including coordination, data management, funding constraints, language barriers, and authorship concerns, while highlighting the measures taken to address them.ConclusionCollaborative virtual models offer a dynamic new frontier in medical research and are vital to studying rare diseases. The COVAD study demonstrates the potential of online platforms for conducting large‐scale, patient‐focused research and underscores the importance of integrating patient perspective into clinical care. Care of patients is our central motivation, and it is essential to recognize their voices as equal stakeholders and valued partners in the study of the conditions that affect them.